Biodesix Inc (BDSX) FinancialsBDSXFinancialBiodesix Inc

Biodesix Inc (BDSX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Lung Diagnostic Testing, accounting for 94.4% of total sales, equivalent to $25.35M. Another important revenue stream is Development Services. Understanding this composition is critical for investors evaluating how BDSX navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Biodesix Inc maintains a gross margin of 82.06%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -20.01%, while the net margin is -27.08%. These profitability ratios, combined with a Return on Equity (ROE) of -540.01%, provide a clear picture of how effectively BDSX converts its operational activities into shareholder value.

In the context of the broader market, BDSX competes directly with industry leaders such as AUNA and XGN. With a market capitalization of $322.86M, it holds a significant position in the sector. When comparing efficiency, BDSX's gross margin of 82.06% stands against AUNA's 35.72% and XGN's 61.27%. Such benchmarking helps identify whether Biodesix Inc is trading at a premium or discount relative to its financial performance.

Biodesix's revenue growth is impressive, with Q2 2026 revenue at $26.9 million, up 34% year-over-year. The gross margin stands at 82.06%, showcasing strong profitability potential despite ongoing losses.